Jefferies Reiterates Their Buy Rating on Atara Biotherapeutics

By Ryan Adsit

Jefferies analyst Michael Yee reiterated a Buy rating on Atara Biotherapeutics (NASDAQ: ATRA) today and set a price target of $30. The company’s shares opened today at $15.75.

According to, Yee is a 5-star analyst with an average return of 9.3% and a 59.0% success rate. Yee covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Arbutus Biopharma Corporation, and Proteostasis Therapeutics Inc.

Atara Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $38.50.

The company has a one year high of $23 and a one year low of $11.80. Currently, Atara Biotherapeutics has an average volume of 240.6K.

Based on the recent corporate insider activity of 93 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Atara Biotherapeutics, Inc. operates as a clinical stage biopharmaceutical company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.